ABBOTT SHOULD REPEAT STUDY OF ULTANE LOW-FLOW USE RISK CONDUCTED BY OHMEDA CONSULTANT; WARNING SHOULD REMAIN IN LABELING, FDA COMMITTEE RECOMMENDS
A warning in the labeling of Abbott's anesthetic Ultane should remain in labeling pending review of results from two small studies of Ultane-associated risk in low-flow systems conducted by an Ohmeda consultant, FDA's Anesthetic and Life Support Drugs Advisory Committee determined April 30.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth